NEW YORK (GenomeWeb News) – Quest Diagnostics has entered into an agreement with Goldman Sachs to repurchase about $450 million of its stock, the company said in a document filed with the US Securities and Exchange Commission today.

Quest received an initial 7,242,489 shares of its stock on Monday. The number of shares it will buy back under the accelerated share repurchase agreement will be based on the average of the daily volume-weighted average price per share of its stock during the repurchase period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.